Salarius Pharmaceuticals (SLRX) stock rocketed higher on Wednesday following a massive fall yesterday. The drop the stock experienced on Tuesday was related to its underwritten public offering, which included 2,514,335 shares and pre-funded warrants to purchase another 2,152,331 shares. These were sold for $1.50 per share, resulting in gross proceeds of approximately $7 million.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
While it’s common for a public stock offering to reduce the value of a company’s shares, due to the side effect of a discounted price in the offering and the dilution of shareholder stakes, the stock often recovers when the offering is complete. Investors will note that the Salarius Pharmaceuticals stock offering was set to close today, which explains why the stock has rallied.
Salarius Pharmaceuticals also provided investors with details about what it would do with the net proceeds from the stock offering. It intends to use the funds on clinical development of Salarius’ and Decoy’s research and development programs, pay off certain of Decoy’s outstanding promissory notes, and for other general corporate purposes.
Salarius Pharmaceuticals Stock Movement Today
Salarius Pharmaceuticals stock was up 66.33% on Wednesday, following a 51% fall yesterday. The stock has decreased 96.45% year-to-date and 95.37% over the past 12 months.
With today’s news came heavy trading of SLRX stock, as more than 27 million shares changed hands, compared to a three-month daily average of about 356,000 units. The stock also saw heavy trading yesterday, when roughly 5.87 million shares were exchanged.
Is Salarius Pharmaceuticals Stock a Buy, Sell, or Hold?
Turning to Wall Street, analyst coverage of Salarius Pharmaceuticals is lacking. Fortunately, TipRanks’ AI analyst Spark has it covered. Spark rates SLRX stock an Underperform (30) with no price target. It cites “significant financial instability, characterized by declining revenues and persistent losses” as reasons for this stance.
